Experimental HIV vaccine passes early safety check in 68 volunteers
NCT ID NCT04844775
First seen Jun 11, 2026 · Last updated Jun 11, 2026
Summary
This early-stage trial tested whether an experimental HIV vaccine is safe and can trigger an immune response. It involved 68 healthy adults who were not infected with HIV. The vaccine uses a DNA-based platform (DREP) alone or with a protein boost. The main goal was to check for side effects and measure antibody production.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUV
Lausanne, Canton of Vaud, 1011, Switzerland
-
CIC Cochin
Paris, Paris Cedex 14, 75679, France
-
Chelsea and Westminster Hospital
London, SW10 9NH, United Kingdom
-
Hôpital Henri Mondor
Créteil, Paris, 94010, France
Conditions
Explore the condition pages connected to this study.